Institute of Biomedical Research Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Drasko D. Pekovic
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Ljubljanska bb Podgorica Montenegro 81000
- IPO Date
- Jul 29, 2004
- Website
- mrescorp.com
- Similar Companies
- Business
- Institute of Biomedical Research Corp. (OTC: MRES) operates as a biomedical research and development company focused on scientific research, quality control, standardization of pharmaceuticals, cosmetics, and food products; development of diagnostic technologies and experimental medical treatments; regulatory control of industrial activities and products; scientific surveillance of the living environment; regulatory evaluation and certification of biomedical products; fundamental scientific research; and graduate research programs in biomedical and environmental fields. The company researches and develops new biomedical and food products, including alternative plant-based cannabinoids, medical psilocybin, and mental health therapeutics powered by artificial intelligence; it also manufactures healthcare devices such as two-channel analog NMS, digital muscle stimulators, digital TENS units, interferential devices, elite combination units, portable four-channel digital stimulators, portable ultrasound devices, photon red light beauty therapy products, electric pain relief systems, microcurrent electrical nerve stimulators, and high-volt pulsed stimulators. Founded in 2010 and headquartered in Podgorica, Montenegro, with a representative office in Montreal, Canada, and new offices in the Biotech Research Center at South Lake Union, Seattle, Washington, the company conducts operations primarily in Montenegro and internationally, positioning itself in the biotechnology, nutraceutical, and life sciences tools sectors while trading as M2Bio Sciences, the "gut and brain company" emphasizing plant-based food and medicine. In recent developments, the company announced in July 2023 an application for a name change and new ticker symbol to align with M2Bio Sciences brands and assets in anticipation of future mergers and acquisitions, strategic growth in biotechnology and phytomedicine, and uplisting to a senior exchange; it continues to expand through AI-powered initiatives in CBD products and psilocybin research, alongside presence at European and U.S. conferences through 2024.
RLAB & MRES: Tiago Henriques Joins M2MMA Combat Sports Promotion Advisory Board
MRES: Dr. Esmarilda Dankaert Appointed Chief Innovation Officer (CINO) at M2Bio Sciences
MRES: M2Bio Food and Beverage Refocuses Strategy: Expanding Beyond CBD to Reach Global Consumers
RLAB: M2MMA Welcomes Legendary Muay Thai Icon Sagat Petchyindee to Advisory Board!
MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead
MRES: M2Bio Sciences Provides Corporate Update
MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development
MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward
MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward
Real American Announces Acquisition of M2MMA from MRES
Real American Announces Appointment of Officers and Directors
MRES: M2MMA Gears Up for a Landmark Year in 2024
MRES: M2Bio Sciences Expands Global Presence with New Offices in Dubai Science Park
MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office
African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair
M2MMA Announces 2024 Fight Schedule and Appoints CEO
M2Bio Sciences Chair, Prof Maharaj, to Deliver Keynote Address on Cutting-Edge Biotechnology Advancements
M2Bio Sciences Closes JDAX Acquisition
M2Bio Sciences Pharmacology & Clinical Application of CBD
M2Bio-Discovery Centre for AI-Driven Phytomedicine Research: Update